Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

CD40-activated B cell cancer vaccine improves second clinical remission and survival in privately owned dogs with non-Hodgkin's lymphoma.

Sorenmo KU, Krick E, Coughlin CM, Overley B, Gregor TP, Vonderheide RH, Mason NJ.

PLoS One. 2011;6(8):e24167. doi: 10.1371/journal.pone.0024167. Epub 2011 Aug 31.

2.

Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Plosker GL, Figgitt DP.

Drugs. 2003;63(8):803-43. Review.

PMID:
12662126
3.

RNA-loaded CD40-activated B cells stimulate antigen-specific T-cell responses in dogs with spontaneous lymphoma.

Mason NJ, Coughlin CM, Overley B, Cohen JN, Mitchell EL, Colligon TA, Clifford CA, Zurbriggen A, Sorenmo KU, Vonderheide RH.

Gene Ther. 2008 Jul;15(13):955-65. doi: 10.1038/gt.2008.22. Epub 2008 Mar 13.

PMID:
18337841
4.

[Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].

Huang HQ, Bu Q, Xia ZJ, Lin XB, Wang FH, Li YH, Peng YL, Pan ZH, Wang SS, Lin TY, Jiang WQ, Guan ZZ.

Ai Zheng. 2006 Apr;25(4):486-9. Chinese.

PMID:
16613686
5.

CD40-independent natural killer-cell help promotes dendritic cell vaccine-induced T-cell immunity against endogenous B-cell lymphoma.

Hömberg N, Adam C, Riedel T, Brenner C, Flatley A, Röcken M, Mocikat R.

Int J Cancer. 2014 Dec 15;135(12):2825-33. doi: 10.1002/ijc.28932. Epub 2014 May 8.

6.

[Therapy of relapsed or refractory non-Hodgkin's lymphoma by antigen specific dendritic cells-activated lymphocytes].

Sun Y, Chen J, Cai P, Hu YH, Zhong GC, Feng HZ, Min M, Li S, Zhang C.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010 Feb;18(1):219-23. Chinese.

PMID:
20137151
7.

Impact of CD40 expression by flowcytometry on outcome of patients with non-Hodgkin's lymphoma.

Soliman MA, Fathy AA, Alkilani A, Abd El-Bary N, El-Bassal F.

Egypt J Immunol. 2009;16(1):61-70.

PMID:
20726323
8.

Genetic idiotypic and tumor cell-based vaccine strategies for indolent non Hodgkin's lymphoma.

Ruffini PA, Di Nicola M, Carlo-Stella C, Siena S, Gianni AM.

Curr Gene Ther. 2005 Oct;5(5):511-21. Review.

PMID:
16250891
9.

CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses.

Rosalia RA, Cruz LJ, van Duikeren S, Tromp AT, Silva AL, Jiskoot W, de Gruijl T, Löwik C, Oostendorp J, van der Burg SH, Ossendorp F.

Biomaterials. 2015 Feb;40:88-97. doi: 10.1016/j.biomaterials.2014.10.053. Epub 2014 Nov 26.

PMID:
25465442
10.

Stimulation of non-Hodgkin's lymphoma via HVEM: an alternate and safe way to increase Fas-induced apoptosis and improve tumor immunogenicity.

Costello RT, Mallet F, Barbarat B, Schiano De Colella JM, Sainty D, Sweet RW, Truneh A, Olive D.

Leukemia. 2003 Dec;17(12):2500-7.

PMID:
14562115
11.

Vaccination with immature dendritic cells combined with CD40mAb induces protective immunity against B lymphoma in hu-SCID mice.

Ge Y, Xi H, Zhang XG.

Biomed Pharmacother. 2010 Sep;64(7):487-92. doi: 10.1016/j.biopha.2010.01.004. Epub 2010 Mar 4.

PMID:
20382498
12.

Vaccine strategies in the treatment of low-grade non-Hodgkin lymphoma.

Koumarianou A, Kountourakis P, Economopoulos T.

J Steroid Biochem Mol Biol. 2008 Apr;109(3-5):230-2. doi: 10.1016/j.jsbmb.2008.03.008. Epub 2008 Mar 7.

PMID:
18406604
13.

Promising long-term outcome of gemcitabine, vinorelbine, liposomal doxorubicin (GVD) in 14-day schedule as salvage regimen for patients with previously heavily treated Hodgkin's lymphoma and aggressive non-Hodgkin's lymphoma.

Bai B, Huang HQ, Cai QQ, Wang XX, Cai QC, Lin ZX, Gao Y, Xia Y, Bu Q, Guo Y.

Med Oncol. 2013 Mar;30(1):350. doi: 10.1007/s12032-012-0350-5. Epub 2013 Jan 18.

PMID:
23329307
14.

Ex vivo induction of viral antigen-specific CD8 T cell responses using mRNA-electroporated CD40-activated B cells.

Van den Bosch GA, Ponsaerts P, Nijs G, Lenjou M, Vanham G, Van Bockstaele DR, Berneman ZN, Van Tendeloo VF.

Clin Exp Immunol. 2005 Mar;139(3):458-67.

15.

Interleukin-13 responsiveness and interleukin-13 receptor expression in non-Hodgkin's lymphoma and reactive lymph node B cells. Modulation by CD40 activation.

Billard C, Caput D, Vita N, Ferrara P, Orrico M, Gaulard P, Boumsell L, Bensussan A, Farcet JP.

Eur Cytokine Netw. 1997 Mar;8(1):19-27.

PMID:
9110144
16.

Failure to define window of time for autologous tumor vaccination in patients with newly diagnosed or relapsed acute lymphoblastic leukemia.

Haining WN, Cardoso AA, Keczkemethy HL, Fleming M, Neuberg D, DeAngelo DJ, Stone RM, Galinsky I, Silverman LB, Sallan SE, Nadler LM, Guinan EC.

Exp Hematol. 2005 Mar;33(3):286-94.

PMID:
15730852
17.

Immunotherapy for non-Hodgkin's lymphoma: monoclonal antibodies and vaccines.

Maloney DG.

J Clin Oncol. 2005 Sep 10;23(26):6421-8. Review.

PMID:
16155029
18.
19.

Enhanced therapeutic effect of B cell-depleting anti-CD20 antibodies upon combination with in-situ dendritic cell vaccination in advanced lymphoma.

Manzur S, Cohen S, Haimovich J, Hollander N.

Clin Exp Immunol. 2012 Dec;170(3):291-9. doi: 10.1111/j.1365-2249.2012.04658.x.

20.

Autotransplantation for advanced lymphoma and Hodgkin's disease followed by post-transplant rituxan/GM-CSF or radiotherapy and consolidation chemotherapy.

Rapoport AP, Meisenberg B, Sarkodee-Adoo C, Fassas A, Frankel SR, Mookerjee B, Takebe N, Fenton R, Heyman M, Badros A, Kennedy A, Jacobs M, Hudes R, Ruehle K, Smith R, Kight L, Chambers S, MacFadden M, Cottler-Fox M, Chen T, Phillips G, Tricot G.

Bone Marrow Transplant. 2002 Feb;29(4):303-12.

Supplemental Content

Support Center